In vitro assays of chemotherapeutic sensitivity.

Area of Science:

• Oncology
• Pharmacology
• Biomedical Assays

Background:

• Designing in vitro assays to predict in vivo antineoplastic drug activity is crucial for optimizing cancer treatment regimens.
• Early assays based on cytotoxicity, dye exclusion, and radiolabeled precursor incorporation showed limited predictive specificity.
• The clonogenic assay, particularly its application to bone marrow stem cells, has emerged as a more promising approach.

Purpose of the Study:

• To review the historical development and current status of in vitro assays for predicting antineoplastic drug activity.
• To highlight the advancements and persistent challenges associated with the clonogenic assay in cancer research.

Main Methods:

• Review of historical and recent studies on in vitro chemosensitivity assays.
• Focus on the evolution and application of the clonogenic assay.
• Discussion of technical challenges, including tumor specimen growth rates and pharmacologic considerations.

Main Results:

• Initial cytotoxicity and dye exclusion assays demonstrated insufficient predictive value.
• The clonogenic assay has been applied to preclinical screening, cytogenetics, and growth factor identification.
• A significant limitation is the poor growth of most tumor specimens in vitro, yielding data in only 30-40% of cases.

Conclusions:

• The clonogenic assay has advanced significantly but faces challenges in specimen growth and requires further validation.
• Pharmacologic considerations are essential to ensure in vitro drug exposure mimics clinical scenarios.
• More prospective clinical trials are needed to establish the reliability of in vitro assays in predicting patient responses.